BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a proven alternative to open heart surgery in elderly patients. Pulmonary hypertension (PH) is known as a significant risk factor in patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement. However, the prognostic impact of PH in high-risk patients undergoing TAVI is still unknown. The aim of this study was to gain more insight in the clinical outcome and mortality of patients with PH after TAVI. METHODS AND RESULTS: Between July 2009 and September 2012, a total of 439 patients were treated by TAVI in conjunction with a complete invasive right heart study at our institution. Patients were divided into two groups with regard to their pulmonary arterial mean pressure (PAMP) before TAVI (A: PAMP < 25 mmHg and B: PAMP ≥ 25 mmHg). Patients with baseline PH had a significantly higher logES (A: 19.40 vs. B: 28.17 %; p < 0.001) and were more frequently in NYHA functional class IV (A: 15.4 vs. B: 25.1 %; p = 0.013). Invasive right heart data demonstrated an immediate improvement after TAVI in patients with PH. Despite a similar clinical benefit among survivors, 30-day and 1-year mortality were higher in patients with PH (30-day mortality: A: 4.8 vs. B: 10.4 %; p = 0.021, 1 year mortality: A: 13.9 vs. B: 23.4 %; p = 0.014). CONCLUSIONS: Pulmonary hypertension is an independent risk factor for survival after TAVI. Nevertheless, TAVI leads to an acute improvement of nearly all invasively assessed variables in patients with PH, with a similar improvement in functional NYHA class compared to patients without PH, indicating a similar benefit among survivors.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a proven alternative to open heart surgery in elderly patients. Pulmonary hypertension (PH) is known as a significant risk factor in patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement. However, the prognostic impact of PH in high-risk patients undergoing TAVI is still unknown. The aim of this study was to gain more insight in the clinical outcome and mortality of patients with PH after TAVI. METHODS AND RESULTS: Between July 2009 and September 2012, a total of 439 patients were treated by TAVI in conjunction with a complete invasive right heart study at our institution. Patients were divided into two groups with regard to their pulmonary arterial mean pressure (PAMP) before TAVI (A: PAMP < 25 mmHg and B: PAMP ≥ 25 mmHg). Patients with baseline PH had a significantly higher logES (A: 19.40 vs. B: 28.17 %; p < 0.001) and were more frequently in NYHA functional class IV (A: 15.4 vs. B: 25.1 %; p = 0.013). Invasive right heart data demonstrated an immediate improvement after TAVI in patients with PH. Despite a similar clinical benefit among survivors, 30-day and 1-year mortality were higher in patients with PH (30-day mortality: A: 4.8 vs. B: 10.4 %; p = 0.021, 1 year mortality: A: 13.9 vs. B: 23.4 %; p = 0.014). CONCLUSIONS:Pulmonary hypertension is an independent risk factor for survival after TAVI. Nevertheless, TAVI leads to an acute improvement of nearly all invasively assessed variables in patients with PH, with a similar improvement in functional NYHA class compared to patients without PH, indicating a similar benefit among survivors.
Authors: F Roques; S A Nashef; P Michel; E Gauducheau; C de Vincentiis; E Baudet; J Cortina; M David; A Faichney; F Gabrielle; E Gams; A Harjula; M T Jones; P P Pintor; R Salamon; L Thulin Journal: Eur J Cardiothorac Surg Date: 1999-06 Impact factor: 4.191
Authors: Spencer J Melby; Marc R Moon; Brian R Lindman; Marci S Bailey; Laureen L Hill; Ralph J Damiano Journal: J Thorac Cardiovasc Surg Date: 2011-06 Impact factor: 5.209
Authors: Juan F Delgado; Esther Conde; Violeta Sánchez; Fernando López-Ríos; Miguel A Gómez-Sánchez; Pilar Escribano; Teresa Sotelo; Agustín Gómez de la Cámara; José Cortina; Carlos S de la Calzada Journal: Eur J Heart Fail Date: 2005-10 Impact factor: 15.534
Authors: Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau Journal: Eur Heart J Date: 2009-08-27 Impact factor: 29.983
Authors: Manuel Carnero-Alcázar; Fernando Reguillo-Lacruz; Ali Alswies; Enrique Villagrán-Medinilla; Luis Carlos Maroto-Castellanos; Joséenrique Rodríguez-Hernández Journal: Interact Cardiovasc Thorac Surg Date: 2010-01-25
Authors: Matthias Eberhard; Monika Mastalerz; Jovana Pavicevic; Thomas Frauenfelder; Fabian Nietlispach; Francesco Maisano; Felix C Tanner; Thi Dan Linh Nguyen-Kim Journal: Int J Cardiovasc Imaging Date: 2017-05-26 Impact factor: 2.357
Authors: Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli Journal: Front Cardiovasc Med Date: 2018-05-23
Authors: Łukasz Wiewiórka; Robert Sobczyński; Jarosław Trębacz; Jerzy Sadowski; Dariusz Dudek; Maciej Stąpór; Janusz Konstanty-Kalandyk; Robert Musiał; Andrzej Gackowski; Krzystof Malinowski; Paweł Kleczyński; Krzysztof Żmudka; Bogusław Kapelak; Jacek Legutko Journal: Postepy Kardiol Interwencyjnej Date: 2021-03-27 Impact factor: 1.426